HBV pgRNA在慢性乙型肝炎进程中的可能意义

谭宁; 罗皓; 徐小元

doi:10.3969/j.issn.1001-5256.2018.10.035

HBV pgRNA在慢性乙型肝炎进程中的可能意义

DOI: 10.3969/j.issn.1001-5256.2018.10.035

北京大学第一医院感染疾病科

基金项目:

传染病国家科技重大专项(2017ZX10302201-004-009)；北京市科技计划项目(D161100002716003;D161100002716002; D171100003117005)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3323
- HTML全文浏览量: 93
- PDF下载量: 486
- 被引次数: 0
出版历程
- 收稿日期: 2018-05-28
- 出版日期: 2018-10-20

Significance of hepatitis B virus pregenomic RNA in the progression of chronic hepatitis B

Department of Infectious Diseases, Peking University First Hospital

Research funding:

摘要

摘要: HBV pgRNA是HBV cccDNA的直接转录产物,能够通过反映HBV cccDNA的转录活动状态进而反映慢性乙型肝炎病情进展,指导临床治疗和判断预后。与其他常用HBV感染血清标志物相比,HBV pgRNA在反映HBV复制活动和抗病毒治疗效果等方面更灵敏,对于抗病毒治疗阶段终点有预测价值。通过综合HBV pgRNA与HBcrAg、HBV cccDNA的相关性来阐述HBV pgRNA在反映慢性乙型肝炎治疗过程中病情变化的可能意义。
- 肝炎,乙型,慢性 /
- HBV pgRNA /
- HBcrAg /
- 综述
Abstract: Hepatitis B virus ( HBV) pregenomic RNA ( pgRNA) is the direct transcription product of HBV covalently closed circular DNA ( cccDNA) and can reflect the transcriptional activity of HBV cccDNA and the progression of chronic hepatitis B, which provides guidance for clinical treatment and prognostic prediction. Compared with other common serological markers for HBV infection, HBV pgRNA is more sensitive in reflecting HBV replication and the effect of antiviral therapy has a certain predictive value for endpoints in the stages of antiviral therapy. This article elaborates on the significance of HBV pgRNA in reflecting the changes in disease conditions with reference to the correlation of HBV pgRNA with HBcrAg and HBV cccDNA.
- hepatitis B, chronic /
- HBV pregenomic RNA /
- hepatitis B core-related antigen /
- review

HTML全文

参考文献(29)

[1]LOK AS, ZOULIM F, DUSHEIKO G, et al.Hepatitis B cure:From discovery to regulatory approval[J].J Hepatol, 2017, 67 (4) :847-861.

[2]YANG HC, CHEN PJ.The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA[J].Virus Res, 2018, 244:304-310.

[3]European Association for the Study of the Liver.EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J].J Hepatol, 2017, 67 (2) :370-398.

[4]KESHVARI M, SALI S, SHARAFI H, et al.P0594:Can serum level of hepatitis B surface antigen (HBsAg) differentiate HBsAg inactive carrier state from chronic hepatitis B?[J].J Hepatol, 2015, 62:s539.

[5]HONER ZU SIEDERDISSEN C, MAASOUMY B, CORNBERG M.What is new on HBsAg and other diagnostic markers in HBV infection?[J].Best Pract Res Clin Gastroenterol, 2017, 31 (3) :281-289.

[6]ZEISEL MB, LUCIFORA J, MASON WS, et al.Towards an HBVcure:state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure[J].Gut, 2015, 64 (8) :1314-1326.

[7]URBAN S, SCHULZE A, DANDRI M, et al.The replication cycle of hepatitis B virus[J].J Hepatol, 2010, 52 (2) :282-284.

[8]SUN S, NAKASHIMA K, ITO M, et al.Involvement of PUF60 in transcriptional and post-transcriptional regulation of hepatitis B virus pregenomic RNA expression[J].Sci Rep, 2017, 7 (1) :12874.

[9]WANG JC, DHASON MS, ZLOTNICK A.Structural organization of pregenomic RNA and the carboxy-terminal domain of the capsid protein of hepatitis B virus[J].PLo S Pathog, 2012, 8 (9) :e1002919.

[10]RYU DK, AHN Y, RYU WS, et al.Development of a novel hepatitis B virus encapsidation detection assay by viral nucleocapsidcaptured quantitative RT-PCR[J].Biotechniques, 2015, 59 (5) :287-293.

[11]WANG J, SHEN T, HUANG X, et al.Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J].J Hepatol, 2016, 65 (4) :700-710.

[12]VAN BOMMEL F, BARTENS A, MYSICKOVA A, et al.Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J].Hepatology, 2015, 61 (1) :66-76.

[13]HALGAND B, DESTERKE C, RIVIERE L, et al.Hepatitis B virus pregenomic RNA in hepatocellular carcinoma:A nosological and prognostic determinant[J].Hepatology, 2018, 67 (1) :86-96.

[14]NASSAL M.HBV ccc DNA:Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J].Gut, 2015, 64 (12) :1972-1984.

[15]JUNG KS, PARK JY, CHON YE, et al.Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients[J].J Gastroenterol, 2016, 51 (8) :830-839.

[16]MATSUZAKI T, TATSUKI I, OTANI M, et al.Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation[J].J Gastroenterol Hepatol, 2013, 28 (7) :1217-1222.

[17]LU FM, WANG J, CHEN XM, et al.The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B[J].Chin J Hepatol, 2017, 25 (2) :105-110. (in Chinese) 鲁凤民, 王杰, 陈香梅, 等.乙型肝炎病毒RNA病毒样颗粒的发现及其对抗病毒治疗临床实践的潜在影响[J].中华肝脏病杂志, 2017, 25 (2) :105-110.

[18]BAI F, YANO Y, FUKUMOTO T, et al.Quantification of pregenomic RNA and covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma[J].Int J Hepatol, 2013, 2013:849290.

[19]HATAKEYAMA T, NOGUCHI C, HIRAGA N, et al.Serum HBVRNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine[J].Hepatology, 2007, 45 (5) :1179-1186.

[20]HUANG H, WANG J, LI W, et al.Serum HBV DNA plus RNAshows superiority in reflecting the activity of intrahepatic ccc DNA in treatment-naive HBV-infected individuals[J].J Clin Virol, 2018, 99-100:71-78.

[21]SETO WK, WONG DK, CHAN TS, et al.Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy[J].Am J Gastroenterol, 2016, 111 (12) :1788-1795.

[22]MAASOUMY B, WIEGAND SB, JAROSZEWICZ J, et al.Hepatitis Bcore-related antigen (HBcr Ag) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D[J].Clin Microbiol Infect, 2015, 21 (6) :606e1-10.

[23]SETO WK, TANAKA Y, WONG DK, et al.Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay[J].Hepatol Int, 2012, 7 (1) :98-105.

[24]LUCKENBAUGH L, KITRINOS KM, DELANEY WET, et al.Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy[J].J Viral Hepat, 2015, 22 (6) :561-570.

[25]CHEN EQ, FENG S, WANG ML, et al.Serum hepatitis B corerelated antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B[J].Sci Rep, 2017, 7 (1) :173.

[26]HONDA M, SHIRASAKI T, TERASHIMA T, et al.Hepatitis B virus (HBV) core-related antigen during nucleos (t) ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma[J].J Infect Dis, 2016, 213 (7) :1096-1106.

[27]LIU RX, PAN XC, GENG J.Clinical value of serum HBV RNA[J].J Clin Hepatol, 2017, 33 (11) :2196-2199. (in Chinese) 刘瑞霞, 潘修成, 耿建.血清HBV RNA检测的临床价值[J].临床肝胆病杂志, 2017, 33 (11) :2196-2199.

[28]TU T, BUDZINSKA MA, VONDRAN FWR, et al.Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles[J].J Virol, 2018, 92 (12) :e02007-e02017.

[29] ARZUMANYAN A, REIS HM, FEITELSON MA.Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma[J].Nat Rev Cancer, 2013, 13 (2) :123-135.

施引文献

资源附件(0)

访问统计